The Risk of Immune-Mediated Skin Disease Under Dipeptidyl-Peptidase IV Inhibitor: A Global Population-Based Study

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)356-358
Number of pages3
JournalInternational Journal of Dermatology
Volume65
Issue number2
Early online date7 Jul 2025
DOIs
StatePublished - Feb 2026

Keywords

  • SGLT-2
  • autoimmune skin diseases
  • dipeptidyl-peptidase IV inhibitor
  • thiazolidinedione

Cite this